Role of CALLA/CD10 Expression in Progression of Melanocytic Tumors: A Study in Egypt

Maha Elsayed Mohammed Salama; Dina Ahmad Khairy

doi:10.3889/oamjms.2021.5916

Authors

Maha Elsayed Mohammed Salama Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt
Dina Ahmad Khairy Department of Pathology, Faculty of Medicine, Beni‑Suef University, Beni Suef, Egypt https://orcid.org/0000-0003-2264-0730

DOI:

https://doi.org/10.3889/oamjms.2021.5916

Keywords:

CD10, verrucous melanoma, Melanocytic nevus, Progression

Abstract

BACKGROUND: Although most of melanocytic lesions can be diagnosed using morphology, there is a significant subset of lesions that are difficult to diagnose. These are a source of anxiety for patients, clinicians, and pathologists. This arouses the possible benefits of using ancillary techniques to solve this problem. CD10 is a zinc-dependent metalloproteinase, its expression is known to be associated with biological aggressiveness in various malignancies.

AIM: This research observes the efficacy of CD10 in the progression of melanocytic tumors as well as the differential diagnosis between nevus and melanoma.

METHODS: The material of this study included 49 paraffin blocks of Egyptian melanocytic tumors. CD10 expression either membranous and/or cytoplasmic in tumor cells was considered positive and scored, based on the percentage of cells stained and compared to Ki67 expression as a prognostic marker.

RESULTS: In benign melanocytic nevi, only 16.7% of cases showed positive expression, all were + 1 score, compared to 82.6% of melanoma cases, mostly +1 score followed by +3 score and finally +2 score. The difference in CD10 expression among melanocytic tumors showed a highly statistically significant correlation between nevus and melanoma cases as well as in Spitz nevi versus other nevi. Another highly statistically significant correlation was observed between CD10 expression and both Ki67 expression and ulceration.

CONCLUSION: CD10 expression was significantly higher expressed in melanomas rather than nevi with highly statistically significant positive relation with Ki67 and ulcer formation which supports its role as a potential biomarker in the development of malignant melanoma and marker of aggression.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Berwick M, Buller DB, Cust A, Gallagher R, Lee TK, Meyskens F, et al. Melanoma Epidemiology and Prevention. Cancer Treat Res. 2016;167:17-49. PMid:26601858 DOI: https://doi.org/10.1007/978-3-319-22539-5_2

Mokhtar N, Salama A, Badawy O, Khorshed E, Mohamed G, Ibrahim M. Cancer Pathology Registry: A 12-Year Registry, 2000-2011. Vol. 13. Bethesda: National Cancer Institute; 2016. p. 192-208.

Harvey NT, Wood BA. A practical approach to the diagnosis of melanocytic lesions. Arch Pathol Lab Med. 2019;143(7):789-810. PMid:30059258 DOI: https://doi.org/10.5858/arpa.2017-0547-RA

Dhande AN, Sinai Khandeparkar SG, Joshi AR, Kulkarni MM, Pandya N, Mohanapure N, et al. Stromal expression of CD10 in breast carcinoma and its correlation with clinicopathological parameters. South Asian J Cancer. 2019;8(1):18-21. https://doi.org/10.4103/sajc.sajc_56_18 PMid:30766845 DOI: https://doi.org/10.4103/sajc.sajc_56_18

Singh L, Marwah N, Bhutani N, Pawar D, Kapil R, Sen R. Study the expression of CD10 in prostate carcinoma and its correlation with various clinicopathological parameters. Iran J Pathol. 2019;14(2):135-45. PMid:31528170

Hoshikawa M, Koizumi H, Handa R. Immunohistochemical CD10 expression is useful for differentiating malignant melanoma from benign melanocytic nevus. J St Marianna Univ 2015;6:111-8. https://doi.org/10.17264/stmarieng.6.111 DOI: https://doi.org/10.17264/stmarieng.6.111

Oba J, Nakahara T, Hayashida S, Kido M, Xie L, Takahara M, et al. Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma. J Am Acad Dermatol. 2011;65(6):1152-60. https://doi.org/10.1016/j.jaad.2010.10.019 PMid:21700362 DOI: https://doi.org/10.1016/j.jaad.2010.10.019

Bilalovic N, Sandstad B, Golouh R, Nesland JM, Selak I, Torlakovic EE. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol. 2004;17(10):1251-8. https://doi. org/10.1038/modpathol.3800174 PMid:15205682 DOI: https://doi.org/10.1038/modpathol.3800174

Kanitakis J, Narvaez D, Claudy A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res. 2002;12(3):241-4. https://doi.org/10.1097/00008390-200206000-00007 PMid:12140380 DOI: https://doi.org/10.1097/00008390-200206000-00007

Velazquez EF, Yancovitz M, Pavlick A, Berman R, Shapiro R, Bogunovic D, et al. Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. J Transl Med. 2007;5(1):2. PMid:17207277 DOI: https://doi.org/10.1186/1479-5876-5-2

Thomas-Pfaab M, Annereau JP, Munsch C, Guilbaud N, Garrido I, Paul C, et al. CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. J Dermatol Sci. 2013;69(2):105-13. https://doi.org/10.1016/j.jdermsci.2012.11.003 PMid:23219141 DOI: https://doi.org/10.1016/j.jdermsci.2012.11.003